- Home
- MGNX vs FURY Comparison
MGNX vs FURY Comparison
Compare MGNX & FURY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- FURY
- Stock Information
- Founded
- MGNX 2000
- FURY 2008
- Country
- MGNX United States
- FURY Canada
- Employees
- MGNX N/A
- FURY N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- FURY Precious Metals
- Sector
- MGNX Health Care
- FURY Basic Materials
- Exchange
- MGNX Nasdaq
- FURY Nasdaq
- Market Cap
- MGNX 99.7M
- FURY 84.1M
- IPO Year
- MGNX 2013
- FURY N/A
- Fundamental
- Price
- MGNX $1.66
- FURY $0.58
- Analyst Decision
- MGNX Hold
- FURY Strong Buy
- Analyst Count
- MGNX 6
- FURY 2
- Target Price
- MGNX $3.20
- FURY $1.40
- AVG Volume (30 Days)
- MGNX 819.6K
- FURY 1.3M
- Earning Date
- MGNX 11-04-2025
- FURY 11-11-2025
- Dividend Yield
- MGNX N/A
- FURY N/A
- EPS Growth
- MGNX N/A
- FURY N/A
- EPS
- MGNX N/A
- FURY N/A
- Revenue
- MGNX $165,495,000.00
- FURY N/A
- Revenue This Year
- MGNX N/A
- FURY N/A
- Revenue Next Year
- MGNX N/A
- FURY N/A
- P/E Ratio
- MGNX N/A
- FURY N/A
- Revenue Growth
- MGNX 303.47
- FURY N/A
- 52 Week Low
- MGNX $0.99
- FURY $0.35
- 52 Week High
- MGNX $5.10
- FURY $0.89
- Technical
- Relative Strength Index (RSI)
- MGNX 45.74
- FURY 38.61
- Support Level
- MGNX $1.82
- FURY $0.57
- Resistance Level
- MGNX $2.15
- FURY $0.62
- Average True Range (ATR)
- MGNX 0.14
- FURY 0.06
- MACD
- MGNX -0.02
- FURY -0.02
- Stochastic Oscillator
- MGNX 16.95
- FURY 1.61
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.